Zydus Cadila gets USFDA nod to market anti-dementia tablets
New Delhi: Zydus Cadila has received final approval from the US health regulator to market Memantine Hydrochloride tablets, used to treat dementia, in America, its listed entity Cadila Healthcare said on Wednesday.
"Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Memantine Hydrochloride tablets USP, 5mg and 10mg," Cadila Healthcare said in a BSE filing.
The company will manufacture the drug at its plant in Moraiya, Ahmedabad.
It has more than 120 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd